Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by 99942Apophison Jul 20, 2022 11:53am
151 Views
Post# 34837223

RE:RE:Beyond the BCG-unresponsive market

RE:RE:Beyond the BCG-unresponsive marketThe Canadian Cancer Society published their 2022 statistics for Bladder cancer.

It is estimated that in 2022:

  • 13,300 Canadians will be diagnosed with bladder cancer.

Key Statistics for Bladder Cancer

 

How common is bladder cancer?

The American Cancer Society’s estimates for bladder cancer in the United States for 2022 are:

  • About 81,180 new cases of bladder cancer (about 61,700 in men and 19,480 in women)
For 2015, the overall number of estimated new cases is about 131,000 (103,000 men and 28,000 women), and it is expected to grow up to 141,000 in 2020.

From the total estimated nnumbers 2022 could see roughly 200K however only 70% will be NMIBC  so yes between 120K to 140K.

Fine and dandy! What about all NMIBC patients currently undergoing other multiple treatments, in my opinion if offered they will also want TLD-1433 so that should cause a much bigger increase to TLT treatment numbers. Do we add another 50K current patient load to that number of 120K to 140K will we be looking at 170K to 190K, numbers are staggering 
<< Previous
Bullboard Posts
Next >>